Limpia V Softgel Capsule is a combination pharmaceutical formulation containing Clindamycin 100 mg, Clotrimazole 100 mg, and Tinidazole 100 mg, designed for the treatment of mixed vaginal infections caused by susceptible bacteria, fungi, and protozoa. Clindamycin, a lincosamide antibiotic, exerts bacteriostatic action by inhibiting bacterial protein synthesis, effectively targeting anaerobic bacteria commonly implicated in bacterial vaginosis. Clotrimazole, an imidazole antifungal agent, disrupts fungal cell membrane synthesis by inhibiting ergosterol production, thereby treating candidal infections. Tinidazole, a nitroimidazole antiprotozoal agent, is effective against protozoal pathogens such as Trichomonas vaginalis by causing DNA strand breakage and inhibiting nucleic acid synthesis. The combined action of these agents provides broad-spectrum coverage against polymicrobial infections of the female lower genital tract. Limpia V Softgel Capsule is indicated for the management of bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis, either as monotherapy or in mixed infections. The softgel formulation facilitates ease of administration and improved bioavailability. Use should be guided by clinical diagnosis and sensitivity patterns, and patients should complete the prescribed course to prevent resistance development. Contraindications include hypersensitivity to any component, and caution is advised in pregnancy and lactation.